NUVB
Nuvation Bio Inc.stockNYSE
nuvation bio is a biopharmaceutical company focused on revolutionizing cancer treatment by discovering, developing and delivering therapies that tackle some of the greatest needs in oncology. nuvation bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. nuvation bio was founded in 2018 by biopharma industry veteran david hung, m.d., who previously founded medivation, inc., which brought to patients one of the world's leading prostate cancer medicines. nuvation bio has offices in new york and san francisco.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 4.06 | 2026-11-12 | -7.14% | 0.523 |
| 1M | 4.48 | 2026-10-19 | -15.85% | 2.018 |
| 3M | 7.26 | 2026-08-19 | -48.07% | 1.959 |
| 6M | 4.24 | 2026-05-19 | -11.09% | 1.624 |
| 1Y | 7.15 | 2025-11-19 | -47.27% | 1.641 |
| 2Y | 2.59 | 2024-11-19 | +45.56% | — |
| 5Y | 9.05 | 2021-11-19 | -58.34% | 1.386 |
Nuvation Bio Inc. (NYSE:NUVB) stock price today is $3.77, and today's volume is 5,957,153. NUVB is down 3.333% today. The 30 day average volume is 5.25M. NUVB market cap is $1.33B with 353.02M shares outstanding.